HLA-B * 27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.
Introduction 1
After infection with hepatitis C virus (HCV), only a minority of patients can clear the 2 virus spontaneously, while >70% of patients develop a chronic infection. Virus-3 specific CD8+ T-cells recognize HCV epitopes that are presented by HLA class I 4 molecules on antigen-presenting cells as well as infected hepatocytes, and are 5 essential effector cells in viral clearance [1] . Specific HLA class I types, such as HLA-6 B*27 and B*57, have a protective role in HCV infection, since they are associated 7 with high rates of spontaneous viral clearance [2, 3] . We could link the protective 8 effect of HLA-B*27 to dominant HLA-B*27 restricted epitopes located in the RNA-9 dependent RNA polymerase of HCV, the NS5B protein [4] . Indeed, one of these 10 epitopes, NS5B 2841 (amino acid sequence ARMILMTHF), is very immunodominant, 11
since it is targeted in nearly all HLA-B*27+ patients with acute or resolved infection. 12
Nearly all HLA-B*27+ patients with chronic infection display multiple viral escape 13 mutations in this epitope. Indeed, we could demonstrate that viral escape from this 14 epitope requires several mutations in order to bypass recognition by the CD8+ T-cell 15 response without deteriorating viral replication capacity. Most likely, this high barrier 16 to viral escape explains why most HLA-B*27+ patients successfully clear the virus in 17 the acute phase of infection, before HCV can escape from the HLA-B*27 restricted 18 CD8+ T-cell response [5] . A second HLA-B*27 restricted CD8+ T-cell epitope located 19 in NS5B (NS5B 2936 , amino acid sequence GRAAICGKY) is subdominantly 20 recognized and selects for viral escape mutations in approx. 50% of chronically HCV-21 infected HLA-B*27+ patients [6] . 22
Next to these two HLA-B*27 restricted epitopes, we initially identified a third HLA-23 B*27 restricted epitope located in NS5B (NS5B 2820 , amino acid sequence 24 ARHTPVNSW) in the same acutely HCV-infected patient of Sicilian (southern Italian) 25 of HLA-B*27+ patients with recovered HCV infection, who were infected with a viral 1 inoculum that contained the respective epitope sequence. Based on a more diverse 2 expression of HLA-B*27 subtypes in southern Italy (subtypes B*27:05, B*27:02, and 3 B*27:09) compared to Ireland (HLA-B*27:05 only) [7] , we hypothesized that the 4 differential targeting of this HLA-B*27 restricted CD8+ T-cell epitope may be due to a 5 limited restriction by certain HLA-B*27 subtypes. Indeed, here we demonstrate that 6 the epitope NS5B 2820 is immunodominant exclusively in the context of HLA-B*27:02. 7
This HLA-B*27 subtype is predominant (>50%) in the Middle East and Northern 8
Africa but is only present in 5-10% of HLA-B*27+ Euro-Caucasians [7] . People that 9 express the ancestral and most common HLA-B*27 subtype HLA-B*27:05, however, 10 do not recognize this epitope. These findings have important implications for vaccine 11 design, since epitope targeting and immunodominance may be impacted not only by 12 individual HLA types, but also by HLA subtypes. 13
Results 1
The NS5B 2820 epitope is vigorously recognized in a Sicilian HLA-B*27+ patient 2 with acute HCV infection, but not in Irish and German HLA-B*27+ patients. 3
We previously identified three HLA-B*27 restricted HCV NS5B-specific CD8+ T-cell 4 epitopes in a Sicilian patient with acute HCV genotype 1a infection [4] . Two of these 5 epitopes, NS5B 2841 (amino acid sequence ARMILMTHF) and NS5B 2936 (amino acid 6 sequence GRAAICGKY) are frequently targeted in HLA-B*27+ patients with resolved 7 or chronic HCV genotype 1 infection. In addition, viral escape mutations are selected 8 in these two epitopes in >90% and ~50%, respectively, of HLA-B*27+ patients with 9 chronic HCV genotype 1 infection [6, 11] . The third HLA-B*27 restricted epitope, 10 NS5B 2820 (amino acid sequence ARHTPVNSW), displayed the strongest interferon-11 gamma response in the acutely infected patient (Fig. 1A) . Strikingly, however, we did 12 not observe any CD8+ T-cell response against this epitope in 6 Irish HLA-B*27+ 13 patients with resolved HCV genotype 1b infection (Fig. 1B) . Importantly, these 14 patients were infected with a single source HCV strain harbouring the wild-type 15 NS5B 2820 epitope sequence, indicating that sequence mismatches in the epitope 16 region cannot explain the lack of recognition. In addition, we were also unable to 17 detect any NS5B 2820 -specific CD8+ T-cell response in 8 HLA-B*27+ German patients 18 with chronic genotype 1b infection (data not shown). Sequence analyses revealed 19 that 6 of the 8 HLA-B*27+ patients had wild-type viral sequences in this epitope 20 region, indicating the absence of substantial immune pressure (Fig. 1C) . 21
Irish HLA-B*27+ individuals primarily express the ancestral and prototype HLA-B*27 22 subtype B*27:05. This subtype is also predominant in German cohorts (reported at 23 >90%). In contrast, in Mediterranean people such as Sicilians the subtype HLA-24 B*27:02 is also frequently expressed. We thus speculated that the expression of 25 different HLA-B*27 subtypes may impact the recognition of the NS5B 2820 epitope. HCV infection is positive for HLA-B*27:02 and not the prototype B*27:05. In order to 5 test the hypothesis that the expression of HLA-B*27:02 may be responsible for the 6 targeting and unusual dominance of the NS5B 2820 epitope, we analyzed the CD8+ T-7 cell response to the three HLA-B*27-restrcited NS5B epitopes in a second HLA-8 B*27:02+ patient with acute resolving HCV genotype 1a infection. Importantly, this 9 patient showed a similar pattern of recognition of the three HLA-B*27-restricted NS5B 10 epitopes, with the NS5B 2820 epitope being the dominant target (supplementary Figure  11   1 ). Next, we tested the ability of HLA-B*27:02 or B*27:05 expressing antigen-12 presenting cells to present the NS5B 2820 peptide to an epitope-specific T-cell line 13 derived from the Sicilian patient. When we loaded HLA-B*27:02 expressing EBV-14 transformed B-cell lines with peptide and co-cultured these cells with an NS5B 2820 -15 specific T-cell line, we indeed observed a strong interferon-gamma response ( Fig. 2A,  16 upper panel). When we used HLA-B*27:05 expressing EBV-transformed B-cell lines, 17 however, we did not observe any interferon-gamma production ( Fig. 2A, lower panel) , 18 even when loading B-cells with 10-fold peptide concentrations (data not shown). The 19 same result was obtained when the B-cell lines were not externally loaded with the 20 epitope peptide, but an endogenous antigen processing experiment was performed 21 using HCV-expressing vaccinia constructs ( Fig. 2A) . Equivalent results were also 22 obtained when NS5B 2820 -specific T-cell lines were used that had been generated 23 from HLA-B*27:02+ patients with spontaneously resolved HCV infection or chronic 24 HCV genotype 1a infection, respectively (supplementary Figure 2) . These data 25 clearly demonstrate that epitope NS5B 2820 is restricted by HLA-B*27:02, but not by 1 the HLA-B*27 prototype B*27:05. 2
We also stimulated PBMC from three HLA-B*27:05+ patients with acute resolving, 3 spontaneously resolved, and chronic HCV genotype 1a infection, respectively, with 4 the NS5B 2820 epitope peptide for two weeks. However, we were unable to detect 5 epitope-specific CD8+ T-cell responses even when using 10-fold peptide 6 concentrations in cell culture and/ or read-out procedures, further indicating that HLA-7 B*27:05+ patients do not target this epitope (data not shown). 8 HLA-B*27:02 is the only HLA-B*27 subtype that has been shown to accept 9 tryptophan (W) at the C-terminus of antigen ligands [12] . The NS5B 2820 epitope has 10 indeed a tryptophan at its C-terminus. We therefore hypothesized that the NS5B 2820 11 epitope peptide may bind specifically to HLA-B*27:02 molecules, but not or only 12
weakly to HLA-B*27:05 molecules. HLA binding analyses indeed showed that the 13 NS5B 2820 peptide has a high affinity for HLA-B*27:02, while it displayed an inferior 14 binding affinity to HLA-B*27:05, when compared to other known HLA-B*27 restricted 15 viral CD8+ T-cell epitopes, including the HCV-specific NS5B 2841 and NS5B 2936 16 epitopes, and also the HIV-specific gag p24 epitope KK10 (Fig. 2B ). The relatively 17 weak binding of NS5B 2820 to HLA-B*27:05 was confirmed in a competition assay 18 using radiolabeled standard peptide (Table 2 ). In silico modeling of the binding of the 19 Since we demonstrated the epitope NS5B 2820 to be specifically restricted by the 6 subtype B*27:02, we aimed to analyze this epitope in a larger cohort of HLA-7 B*27:02+ patients. In order to include a sufficient number of HLA-B*27:02+ patients, 8
we combined data from four large cohorts of patients with chronic HCV genotype 1 9 infection, including a total of 1521 patients. 91 (6.0%) of these patients were HLA-10 B*27+ (Table 1 ). In a total of 78 HLA-B*27+ patients, 4-digit typing of HLA-B*27 as 11 well as viral sequence data for the NS5B region corresponding to the NS5B 2820 12 epitope could be obtained. Importantly, in 12 out of 13 (92.3%) HLA-B*27:02+ 13 patients, we observed a sequence variation at amino acid position 2 of the epitope, 14 with a substitution of arginine (R) by lysine (K) ( Table 3) . In contrast, patients that 15 expressed the HLA-B*27 prototype B*27:05 rarely displayed sequence variations 16 compared to the consensus sequence (6/ 59 patients, 10.2%; P<0.0001, Fisher's 17 exact test). Only a single HLA-B*27:05+ patient (1.7%) displayed a mutation at 18 position 2 of the epitope, suggesting that the few mutations occurring in HLA-19 B*27:05+ patients were not driven by NS5B 2820 -specific CD8+ T-cells. Patients 20 expressing rare HLA-B*27 subtypes such as B*27:03, B*27:06, B*27:10, and B*27:14 21
showed similar results compared to HLA-B*27:05+ patients, with only 1 of 6 patients 22 displaying a variant viral sequence. 23
Our findings indicate that NS5B 2820 -specific CD8+ T-cells are strong drivers of viral 24 evolution in HLA-B*27:02+ patients, resulting in the viral escape mutation R2821K at 25 amino acid position 2 of the epitope. Arginine (R) at this position functions as themain HLA-B*27 binding anchor, thus, mutational escape at this position is likely to 1 have a strong impact on epitope presentation. Indeed, the R2821K mutant peptide 2 displayed only marginal binding to the HLA-B*27:02 molecule as compared to the 3 wild-type peptide (Fig. 4A) . We next tested recognition of the consensus as well as 4 variant peptide by epitope-specific cell lines generated from the patient with acute 5 infection. As shown in Fig. 4B (upper panel) , the R2821K mutation completely 6 abolished recognition of the epitope peptide, demonstrating that this viral variation 7 does indeed represent a viral escape mutation. 8
We also tested PBMC from five HLA-B*27:02+ patients with chronic HCV genotype 1 9 infection and PBMC from one HLA-B*27:02+ patient with spontaneously resolved 10 HCV infection for NS5B 2820 -specific CD8+ T-cell responses after two weeks of 11 peptide-specific cell culture. In one out of the five chronically infected patients as well 12 as in the patient with resolved infection, we were successful in generating epitope-13 specific CD8+ T-cell lines with strong interferon-gamma production in response to the 14 consensus, but not the R2821K variant peptide ( variant by performing peptide titration assays for the NS5B 2820 -specific T-cell lines 20 (Fig. 4C) . Of note, the partial cross-recognition of the mutant peptide in the 21 chronically infected patient in this assay (Fig. 4C ) in contrast to the lack of cross-22 recognition after loading of the mutant peptide on HLA-B*27:02+ B-cells with 23 subsequent washing of the B-cells prior to co-culture with the epitope-specific T-cell 24 line (Fig. 4B) indicates that the variant peptide binds to HLA-B*27:02 with low affinity, 25 resulting in a high drop-off rate.
It has been described that certain viral mutant peptides may have antagonistic 1 capacities and compete with their respective wild-type peptide for HLA and/or TCR 2 binding [17] . Thus, we performed competition assays titrating increasing doses of the 3 mutant peptide in addition to the wild-type peptide, however, we observed no 4 antagonistic effect (Fig. 4D) . 5
In summary, we clearly show that the epitope NS5B 2820 is specifically restricted by 6 HLA-B*27:02, but not by the prototype HLA-B*27 subtype B*27:05. In the context of 7 HLA-B*27:02, viral escape mutations are selected in the vast majority of patients. 8
These results suggest that HLA class I subtypes have an important impact in 9 directing the HCV-specific CD8+ T-cell response.
Discussion 1
We have previously identified three HLA-B*27 restricted CD8+ T-cell epitopes 2 located in the HCV NS5B protein [4] . Two of these epitopes, NS5B 2841 and NS5B 2936 , 3
were frequently targeted in HLA-B*27+ patients with HCV genotype 1 infection and 4 also reproducibly induced viral escape. In the current study, we analyzed a third HLA-5 B*27 restricted epitope in NS5B. This epitope seemed to be a minor CD8+ T-cell 6 target, since we could not detect CD8+ T-cell responses against this epitope in any of 7 14 HLA-B*27+ patients with resolved or chronic HCV infection. This finding was 8 somewhat in discrepancy with the very strong epitope-specific CD8+ T-cell response 9 observed in a patient with acute HCV infection. HCV genotype or subtype-diversity 10 could not explain this finding, since the epitope is conserved in geno-/subtypes 1a, 11 1b, and also 3a (supplementary table 1). When we analyzed the reason for these 12 discrepant observations, we discovered that the epitope NS5B 2820 is only presented 13 by the HLA-B*27 subtype B*27:02, but not by other HLA-B*27 subtypes, including the 14 prototype HLA-B*27:05. The HLA-B*27:02 subtype-specificity of this epitope may be 15 largely mediated by a superior binding of the epitope peptide to HLA-B*27:02 and an 16 only weak binding to HLA-B*27:05. However, other mechanisms such as naïve 17 precursor frequencies may also have an additional impact [18] . 18
We found that NS5B 2820 is a dominant epitope in HLA-B*27:02 patients, since the 19 vast majority (12 of 13) of HLA-B*27:02+ patients with chronic HCV infection 20 displayed a viral escape mutation at the main HLA binding anchor of the epitope. 21
Since this epitope is only restricted by the relatively rare subtype HLA-B*27:02, but 22 not by the common 'ancestral' B*27:05, it is by mistake considered not to be 
responses. 24
While these findings clearly need to be confirmed in additional studies performed in 25 cohorts with differential ethnical backgrounds, they indicate that vaccine candidatesthat have been designed considering HLA class I prototypes only may exclude 1 protective CD8+ T-cell epitopes restricted by minor HLA subtypes. In this scenario, it 2 is important to note that rare HLA types and subtypes may predominantly contribute 3 to viral control [23] . As a consequence, vaccine studies should aim at a broad 4 coverage of potential CD8+ epitopes and also include comprehensive analyses using 5 e.g. overlapping peptides in their read-outs in order to avoid a bias towards prototype 6 HLA subtypes. 7
In conclusion, we demonstrate here that HLA class I subtypes may have an important 8 role in restriction of HCV-specific CD8+ T-cell epitopes. This is highlighted in our 9 study of an HLA-B*27 restricted CD8+ T-cell epitope that is immunodominant in the 10 background of HLA-B*27:02, but not presented by other HLA-B*27 subtypes, 11 including the prototype HLA-B*27:05. 12
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